Headline: Bioxytran’s PHM23 Selected for USDA’s $100M Avian Influenza Innovation Challenge

In a significant development for the food and beverage industry, Bioxytran, Inc. (OTCQB: BIXT) announced that its antiviral PHM23 has been included in the University of Georgia’s grant submission to the U.S. Department of Agriculture’s (USDA) $100 million Highly Pathogenic Avian Influenza (HPAI) Poultry Innovation Grand Challenge. This recognition underscores PHM23’s potential as a groundbreaking solution to combat Bird Flu (H5N1) and highlights its broad-spectrum antiviral activity.

Advancing Antiviral Solutions

University of Georgia’s Validation

• The University of Georgia, a global leader in poultry health, selected PHM23 as a promising therapeutic candidate for viral infections.
• PHM23’s inclusion in this high-profile submission amplifies awareness of its antiviral activity and potential impact on poultry health.
• By targeting galectins critical to viral replication, PHM23 demonstrates effectiveness against viruses similar to Bird Flu in in vitro studies.
  

  Transformative Potential
  

• CEO David Platt emphasized the transformative potential of complex carbohydrate-based antiviral drugs in addressing global agriculture challenges.
• PHM23’s selection validates Bioxytran’s innovative galectin antagonist platform and its role in safeguarding animal health and food supply.
• Collaborations with leading academic institutions highlight the industry’s commitment to advancing breakthrough therapies.
  

  Galectin Antagonist Technology
  

• PHM23’s mechanism of action involves blocking viral spike proteins from attaching to host cells, minimizing the risk of viral mutations.
• This approach offers hope for rapid containment of H5N1 outbreaks, potentially reducing the need for mass culling and mitigating industry losses.
• Bioxytran is actively seeking partnerships to accelerate PHM23’s development and deployment in response to global poultry health needs.
  

  About Bioxytran, Inc.
  

• Bioxytran focuses on developing complex carbohydrate-based therapeutics in virology, cancer metastasis, and oxygen transport.
• The company’s innovative platforms address critical unmet medical needs, including programs for pulmonary fibrosis and stroke treatment.
• Bioxytran’s commitment to advancing medical solutions underscores its dedication to transforming the healthcare landscape.
  

  Industry Analysis
  

  The inclusion of Bioxytran’s PHM23 in the USDA’s HPAI Poultry Innovation Grand Challenge marks a significant milestone for the global food and beverage industry. This development could have far-reaching implications, including:

• Supply Chains: The adoption of PHM23 as an antiviral solution could enhance biosecurity measures in poultry production, safeguarding supply chains.
• Pricing: Increased efficiency in combating avian influenza could lead to more stable pricing in the poultry industry, benefiting producers and consumers.
• Trade Dynamics: Improved disease management through innovative therapies like PHM23 could strengthen international trade relations in the poultry sector.
• Strategic Outlook: Bioxytran’s advancements in antiviral technology pave the way for future collaborations and innovations in addressing global health challenges.

  In conclusion, Bioxytran’s selection for the USDA’s avian influenza innovation challenge highlights the industry’s commitment to advancing solutions that protect animal health, ensure food security, and drive transformative change in the food and beverage sector. By harnessing the power of innovative technologies like PHM23, food and beverage professionals can navigate challenges and seize opportunities for a sustainable future.